These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18676156)

  • 1. The biological properties of cetuximab.
    Vincenzi B; Schiavon G; Silletta M; Santini D; Tonini G
    Crit Rev Oncol Hematol; 2008 Nov; 68(2):93-106. PubMed ID: 18676156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab: from bench to bedside.
    Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
    Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
    Panikkar RP; Astsaturov I; Langer CJ
    Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab in advanced non-small cell lung cancer.
    Govindan R
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4241s-4244s. PubMed ID: 15217966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab in the treatment of head and neck cancer.
    Bernier J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1539-52. PubMed ID: 17134359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
    Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
    J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
    Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
    Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
    Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
    Moon C; Chae YK; Lee J
    Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for cetuximab in non small cell lung cancer?
    Morgensztern D; Govindan R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.
    Bellone S; Frera G; Landolfi G; Romani C; Bandiera E; Tognon G; Roman JJ; Burnett AF; Pecorelli S; Santin AD
    Gynecol Oncol; 2007 Sep; 106(3):513-20. PubMed ID: 17540437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
    Huang SM; Harari PM
    Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab in combination therapy: from bench to clinic.
    Gerber DE; Choy H
    Cancer Metastasis Rev; 2010 Mar; 29(1):171-80. PubMed ID: 20140759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.